Stivarga | Regorafenib (download only)

Regular price $0.00

 

Stivarga (regorafenib) is a treatment is designed to target cancer cells and the blood vessels feeding them by interfering with chemical signals or pathways inside abnormal cells.

The treatment comes in pill form and is known as a tyrosine kinase inhibitor (TKI).

Stivarga  targets the signaling of multiple growth factors involved in tumor angiogenesis, including VEGF receptors, Fibroblast Growth Factor (FGF) receptors, Platelet-Derived Growth Factor (PDGF) receptors, and the angiopoietin receptor TIE-2. Additional targets of regorafenib include RAF, BRAF, RET and KIT.

Stivarga is approved for treating patients with metastatic bowel cancer in the third-line setting, after the cancer has progressed or has recurred after multiple treatments. 

Is Stivarga available on the Pharmaceutical Benefits Scheme (PBS) as a subsidised treatment?

  • Stivarga has been approved by the Therapeutic Goods Administration (TGA) for use in Australia, however, it is not currently listed on the PBS as a subsidised treatment.

Download the Consumer Medicine Information (CMI) for Stivarga.